[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fGBOgVKR_UA8JjjhOnf_p98iG998QVuiTODBV4u-Drog":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":32,"phaseBuckets":63,"rows":70},"Celldex Therapeutics",[4],45,false,7,5,6983,2,0,[14,16,18,20,23,25,27,29],{"name":15,"count":9},"Chronic Spontaneous Urticaria",{"name":17,"count":9},"Breast Cancer",{"name":19,"count":9},"Ovarian Cancer",{"name":21,"count":22},"Bladder Cancer",4,{"name":24,"count":22},"Head and Neck Cancer",{"name":26,"count":22},"Non-small Cell Lung Cancer",{"name":28,"count":22},"Colorectal Cancer",{"name":30,"count":31},"Kidney Neoplasms",3,[33,38,43,47,50,55,59],{"nctId":34,"briefTitle":35,"date":36,"intervention":37},"NCT06727552","A Study of Barzolvolimab in Patients With Atopic Dermatitis","2026-05","Barzolvolimab",{"nctId":39,"briefTitle":40,"date":41,"intervention":42},"NCT06366750","A Study of Barzolvolimab in Patients With Prurigo Nodularis","2026-06","barzolvolimab",{"nctId":44,"briefTitle":45,"date":46,"intervention":42},"NCT06455202","A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria (CSU)","2026-10",{"nctId":48,"briefTitle":49,"date":46,"intervention":42},"NCT06445023","A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria",{"nctId":51,"briefTitle":52,"date":53,"intervention":54},"NCT07330778","A Study of CDX-622 in Participants With Mild to Moderate Asthma","2027-03","CDX-622",{"nctId":56,"briefTitle":57,"date":58,"intervention":37},"NCT07266402","A Study to Investigate Efficacy, Safety and Tolerability of Barzolvolimab Versus Placebo in Adults With Cold Induced Urticaria and Symptomatic Dermographism Inadequately Controlled by H1-antihistamines (EMBARQ - ColdU and SD)","2028-06",{"nctId":60,"briefTitle":61,"date":62,"intervention":42},"NCT07256392","Long-term Efficacy and Safety Extension (LTE) Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria","2028-09",[64,65,66,67,68,69],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[71,165,197,240,271,293,374,401,438,456,483,501,519,544,573,591,609,627,656,674,692,710,728,746,771,789,854,888,934,952,985,1010,1028,1046,1072,1101,1126,1151,1176,1208,1233,1257,1283],{"intervention":42,"totalTrials":72,"cells":73},9,{"EARLY_PHASE1":74,"PHASE1":76,"PHASE2":78,"PHASE3":129,"PHASE4":161,"NA":163},{"trials":75,"activeCount":12},[],{"trials":77,"activeCount":12},[],{"trials":79,"activeCount":11,"soonestReadout":36},[80,88,99,110,121],{"nctId":39,"briefTitle":40,"status":81,"phases":82,"primaryCompletion":41,"completion":53,"start":83,"enrollment":84,"conditions":85,"interventions":87},"ACTIVE_NOT_RECRUITING",[66],"2024-04-12",140,[86],"Prurigo Nodularis",[42],{"nctId":89,"briefTitle":90,"status":91,"phases":92,"primaryCompletion":93,"completion":94,"start":95,"enrollment":96,"conditions":97,"interventions":98},"NCT05368285","A Phase 2 Study of CDX-0159 in Patients With Chronic Spontaneous Urticaria","COMPLETED",[66],"2023-09-28","2024-12-20","2022-05-19",208,[15],[42],{"nctId":100,"briefTitle":101,"status":91,"phases":102,"primaryCompletion":103,"completion":104,"start":105,"enrollment":106,"conditions":107,"interventions":109},"NCT05405660","A Study of CDX-0159 in Patients With Chronic Inducible Urticaria",[66],"2024-06-12","2025-09-12","2022-06-28",196,[108],"Chronic Inducible Urticaria",[42],{"nctId":111,"briefTitle":112,"status":91,"phases":113,"primaryCompletion":114,"completion":115,"start":116,"enrollment":117,"conditions":118,"interventions":120},"NCT05774184","A Study of CDX-0159 in Patients With Eosinophilic Esophagitis",[66],"2025-06-04","2026-01-23","2023-06-01",86,[119],"Eosinophilic Esophagitis",[42],{"nctId":34,"briefTitle":35,"status":81,"phases":122,"primaryCompletion":36,"completion":123,"start":124,"enrollment":125,"conditions":126,"interventions":128},[66],"2026-12","2024-12-18",131,[127],"Atopic Dermatitis",[37],{"trials":130,"activeCount":22,"soonestReadout":46},[131,138,145,155],{"nctId":60,"briefTitle":61,"status":132,"phases":133,"primaryCompletion":62,"completion":62,"start":134,"enrollment":135,"conditions":136,"interventions":137},"RECRUITING",[67],"2025-11-25",1370,[15],[42],{"nctId":44,"briefTitle":45,"status":81,"phases":139,"primaryCompletion":46,"completion":140,"start":141,"enrollment":142,"conditions":143,"interventions":144},[67],"2027-04","2024-07-19",976,[15],[42],{"nctId":56,"briefTitle":57,"status":132,"phases":146,"primaryCompletion":58,"completion":147,"start":148,"enrollment":149,"conditions":150,"interventions":154},[67],"2028-10","2026-01-15",240,[108,151,152,153],"Cold Urticaria","Cold-Induced Urticaria","Symptomatic Dermographism",[37],{"nctId":48,"briefTitle":49,"status":81,"phases":156,"primaryCompletion":46,"completion":140,"start":157,"enrollment":158,"conditions":159,"interventions":160},[67],"2024-07-11",963,[15],[42],{"trials":162,"activeCount":12},[],{"trials":164,"activeCount":12},[],{"intervention":54,"totalTrials":11,"cells":166},{"EARLY_PHASE1":167,"PHASE1":169,"PHASE2":189,"PHASE3":191,"PHASE4":193,"NA":195},{"trials":168,"activeCount":12},[],{"trials":170,"activeCount":188,"soonestReadout":53},[171,177],{"nctId":51,"briefTitle":52,"status":132,"phases":172,"primaryCompletion":53,"completion":53,"start":41,"enrollment":173,"conditions":174,"interventions":176},[65],12,[175],"Mild to Moderate Asthma",[54],{"nctId":178,"briefTitle":179,"status":91,"phases":180,"primaryCompletion":181,"completion":181,"start":182,"enrollment":183,"conditions":184,"interventions":186},"NCT06650761","A Phase I Study of CDX-622",[65],"2026-04-24","2024-11-01",85,[185],"Healthy Participants",[54,187],"Normal Saline",1,{"trials":190,"activeCount":12},[],{"trials":192,"activeCount":12},[],{"trials":194,"activeCount":12},[],{"trials":196,"activeCount":12},[],{"intervention":198,"totalTrials":11,"cells":199},"Temozolomide",{"EARLY_PHASE1":200,"PHASE1":202,"PHASE2":204,"PHASE3":218,"PHASE4":236,"NA":238},{"trials":201,"activeCount":12},[],{"trials":203,"activeCount":12},[],{"trials":205,"activeCount":12},[206],{"nctId":207,"briefTitle":208,"status":91,"phases":209,"primaryCompletion":210,"completion":211,"start":212,"enrollment":213,"conditions":214,"interventions":216},"NCT00458601","Phase II Study of Rindopepimut (CDX-110) in Patients With Glioblastoma Multiforme",[66],"2010-11","2016-05","2007-08",82,[215],"Malignant Glioma",[217,198],"CDX-110 with GM-CSF",{"trials":219,"activeCount":12},[220],{"nctId":221,"briefTitle":222,"status":91,"phases":223,"primaryCompletion":224,"completion":224,"start":225,"enrollment":226,"conditions":227,"interventions":233},"NCT01480479","Phase III Study of Rindopepimut\u002FGM-CSF in Patients With Newly Diagnosed Glioblastoma",[67],"2016-11","2011-11",745,[228,229,230,231,232],"Glioblastoma","Small Cell Glioblastoma","Giant Cell Glioblastoma","Gliosarcoma","Glioblastoma With Oligodendroglial Component",[234,198,235],"Rindopepimut (CDX-110) with GM-CSF","KLH",{"trials":237,"activeCount":12},[],{"trials":239,"activeCount":12},[],{"intervention":234,"totalTrials":11,"cells":241},{"EARLY_PHASE1":242,"PHASE1":244,"PHASE2":246,"PHASE3":261,"PHASE4":267,"NA":269},{"trials":243,"activeCount":12},[],{"trials":245,"activeCount":12},[],{"trials":247,"activeCount":12},[248],{"nctId":249,"briefTitle":250,"status":91,"phases":251,"primaryCompletion":252,"completion":253,"start":254,"enrollment":255,"conditions":256,"interventions":259},"NCT01498328","A Study of Rindopepimut\u002FGM-CSF in Patients With Relapsed EGFRvIII-Positive Glioblastoma",[66],"2015-04","2016-05-17","2011-12",127,[228,229,230,231,232,257,258],"Recurrent Glioblastoma","Relapsed Glioblastoma",[260,234,235],"Bevacizumab",{"trials":262,"activeCount":12},[263],{"nctId":221,"briefTitle":222,"status":91,"phases":264,"primaryCompletion":224,"completion":224,"start":225,"enrollment":226,"conditions":265,"interventions":266},[67],[228,229,230,231,232],[234,198,235],{"trials":268,"activeCount":12},[],{"trials":270,"activeCount":12},[],{"intervention":235,"totalTrials":11,"cells":272},{"EARLY_PHASE1":273,"PHASE1":275,"PHASE2":277,"PHASE3":283,"PHASE4":289,"NA":291},{"trials":274,"activeCount":12},[],{"trials":276,"activeCount":12},[],{"trials":278,"activeCount":12},[279],{"nctId":249,"briefTitle":250,"status":91,"phases":280,"primaryCompletion":252,"completion":253,"start":254,"enrollment":255,"conditions":281,"interventions":282},[66],[228,229,230,231,232,257,258],[260,234,235],{"trials":284,"activeCount":12},[285],{"nctId":221,"briefTitle":222,"status":91,"phases":286,"primaryCompletion":224,"completion":224,"start":225,"enrollment":226,"conditions":287,"interventions":288},[67],[228,229,230,231,232],[234,198,235],{"trials":290,"activeCount":12},[],{"trials":292,"activeCount":12},[],{"intervention":294,"totalTrials":31,"cells":295},"CDX-301",{"EARLY_PHASE1":296,"PHASE1":298,"PHASE2":344,"PHASE3":368,"PHASE4":370,"NA":372},{"trials":297,"activeCount":12},[],{"trials":299,"activeCount":12},[300,333],{"nctId":301,"briefTitle":302,"status":91,"phases":303,"primaryCompletion":304,"completion":304,"start":305,"enrollment":306,"conditions":307,"interventions":329},"NCT03329950","A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies",[65],"2022-09-13","2017-12-01",132,[308,26,17,309,310,19,311,312,313,28,314,315,24,316,317,318,319,320,321,322,323,324,325,326,327,328],"Melanoma","Gastric Cancer","Renal Cell Carcinoma","Cholangiocarcinoma","Bladder Urothelial Carcinoma","Pancreatic Adenocarcinoma","Esophageal Cancer","Hepatic Cancer","Primary Peritoneal Cancer","Fallopian Tube Cancer","Other Solid Tumors","Diffuse Large B-cell Lymphoma (DLBCL)","Mantle Cell Lymphoma","Indolent B-cell Lymphomas","Non-Hodgkin Lymphoma","Follicular Lymphoma","Lymphoplasmacytic Lymphoma","Waldenstrom's Disease","Marginal Zone Lymphoma","Mucosa Associated Lymphoid Tissue","Small Lymphocytic Leukemia",[330,294,331,332],"CDX-1140","pembrolizumab","Chemotherapy",{"nctId":334,"briefTitle":335,"status":91,"phases":336,"primaryCompletion":337,"completion":338,"start":339,"enrollment":340,"conditions":341,"interventions":343},"NCT01465139","A Study to Evaluate CDX-301 (rhuFlt3L) in Healthy Volunteers",[65],"2012-11","2013-01","2011-10",30,[342],"Healthy",[294],{"trials":345,"activeCount":12},[346],{"nctId":347,"briefTitle":348,"status":349,"phases":350,"primaryCompletion":351,"completion":352,"start":353,"enrollment":354,"conditions":355,"interventions":366},"NCT02200380","A Safety and Tolerability Study of CDX-301 With or Without Plerixafor for Stem Cell Mobilization in Matched Related Allogeneic Donor\u002FRecipient Sibling Transplant Pairs","TERMINATED",[66],"2016-03","2016-04-13","2014-07",36,[356,357,358,359,360,361,362,363,364,365],"For Donors","Related Donors Giving Peripheral Blood Stem Cells (PBSC) to a Sibling","For Recipients","Acute Myelogenous Leukemia (AML)","Acute Lymphoblastic Leukemia (ALL)","Myelodysplastic Syndrome (MDS)","Chronic Myelogenous Leukemia (CML)","Non-Hodgkins Lymphoma (NHL)","Hodgkins Disease (HD)","Chronic Lymphocytic Leukemia (CLL)",[294,367],"CDX-301 and plerixafor",{"trials":369,"activeCount":12},[],{"trials":371,"activeCount":12},[],{"trials":373,"activeCount":12},[],{"intervention":332,"totalTrials":11,"cells":375},{"EARLY_PHASE1":376,"PHASE1":378,"PHASE2":384,"PHASE3":395,"PHASE4":397,"NA":399},{"trials":377,"activeCount":12},[],{"trials":379,"activeCount":12},[380],{"nctId":301,"briefTitle":302,"status":91,"phases":381,"primaryCompletion":304,"completion":304,"start":305,"enrollment":306,"conditions":382,"interventions":383},[65],[308,26,17,309,310,19,311,312,313,28,314,315,24,316,317,318,319,320,321,322,323,324,325,326,327,328],[330,294,331,332],{"trials":385,"activeCount":12},[386],{"nctId":387,"briefTitle":388,"status":349,"phases":389,"primaryCompletion":390,"completion":390,"start":391,"enrollment":31,"conditions":392,"interventions":393},"NCT01094496","A Study of the CDX-1307 Vaccine Regimen in Patients With Newly Diagnosed Muscle-Invasive Bladder Cancer (The \"N-ABLE\" Study)",[66],"2011-07","2010-04",[21],[394,332],"CDX-1307 Vaccine Regimen",{"trials":396,"activeCount":12},[],{"trials":398,"activeCount":12},[],{"trials":400,"activeCount":12},[],{"intervention":402,"totalTrials":11,"cells":403},"CDX-011",{"EARLY_PHASE1":404,"PHASE1":406,"PHASE2":408,"PHASE3":432,"PHASE4":434,"NA":436},{"trials":405,"activeCount":12},[],{"trials":407,"activeCount":12},[],{"trials":409,"activeCount":12},[410,422],{"nctId":411,"briefTitle":412,"status":91,"phases":413,"primaryCompletion":414,"completion":415,"start":416,"enrollment":417,"conditions":418,"interventions":420},"NCT01997333","Study of Glembatumumab Vedotin (CDX-011) in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer",[66],"2017-11-30","2018-08-07","2013-11",327,[419],"Metastatic gpNMB Over-expressing Triple Negative Breast Cancer",[402,421],"Capecitabine",{"nctId":423,"briefTitle":424,"status":91,"phases":425,"primaryCompletion":426,"completion":337,"start":427,"enrollment":428,"conditions":429,"interventions":430},"NCT01156753","A Study of CDX-011 (CR011-vcMMAE) in Patients With Advanced GPNMB-expressing Breast Cancer",[66],"2012-10","2010-07",120,[17],[402,431],"\"Investigator's Choice\" chemotherapy",{"trials":433,"activeCount":12},[],{"trials":435,"activeCount":12},[],{"trials":437,"activeCount":12},[],{"intervention":394,"totalTrials":188,"cells":439},{"EARLY_PHASE1":440,"PHASE1":442,"PHASE2":444,"PHASE3":450,"PHASE4":452,"NA":454},{"trials":441,"activeCount":12},[],{"trials":443,"activeCount":12},[],{"trials":445,"activeCount":12},[446],{"nctId":387,"briefTitle":388,"status":349,"phases":447,"primaryCompletion":390,"completion":390,"start":391,"enrollment":31,"conditions":448,"interventions":449},[66],[21],[394,332],{"trials":451,"activeCount":12},[],{"trials":453,"activeCount":12},[],{"trials":455,"activeCount":12},[],{"intervention":457,"totalTrials":188,"cells":458},"glembatumumab vedotin and varlilumab",{"EARLY_PHASE1":459,"PHASE1":461,"PHASE2":463,"PHASE3":477,"PHASE4":479,"NA":481},{"trials":460,"activeCount":12},[],{"trials":462,"activeCount":12},[],{"trials":464,"activeCount":12},[465],{"nctId":466,"briefTitle":467,"status":349,"phases":468,"primaryCompletion":469,"completion":470,"start":471,"enrollment":306,"conditions":472,"interventions":473},"NCT02302339","A Study of Glembatumumab Vedotin as Monotherapy or in Combination With Immunotherapies in Patients With Advanced Melanoma",[66],"2018-06-14","2018-10-03","2014-11",[308],[474,457,475,476],"glembatumumab vedotin","glembatumumab vedotin and PD-1 targeted checkpoint inhibitor","glembatumumab vedotin and CDX-301",{"trials":478,"activeCount":12},[],{"trials":480,"activeCount":12},[],{"trials":482,"activeCount":12},[],{"intervention":475,"totalTrials":188,"cells":484},{"EARLY_PHASE1":485,"PHASE1":487,"PHASE2":489,"PHASE3":495,"PHASE4":497,"NA":499},{"trials":486,"activeCount":12},[],{"trials":488,"activeCount":12},[],{"trials":490,"activeCount":12},[491],{"nctId":466,"briefTitle":467,"status":349,"phases":492,"primaryCompletion":469,"completion":470,"start":471,"enrollment":306,"conditions":493,"interventions":494},[66],[308],[474,457,475,476],{"trials":496,"activeCount":12},[],{"trials":498,"activeCount":12},[],{"trials":500,"activeCount":12},[],{"intervention":476,"totalTrials":188,"cells":502},{"EARLY_PHASE1":503,"PHASE1":505,"PHASE2":507,"PHASE3":513,"PHASE4":515,"NA":517},{"trials":504,"activeCount":12},[],{"trials":506,"activeCount":12},[],{"trials":508,"activeCount":12},[509],{"nctId":466,"briefTitle":467,"status":349,"phases":510,"primaryCompletion":469,"completion":470,"start":471,"enrollment":306,"conditions":511,"interventions":512},[66],[308],[474,457,475,476],{"trials":514,"activeCount":12},[],{"trials":516,"activeCount":12},[],{"trials":518,"activeCount":12},[],{"intervention":520,"totalTrials":188,"cells":521},"CDX-3379 and cetuximab",{"EARLY_PHASE1":522,"PHASE1":524,"PHASE2":526,"PHASE3":538,"PHASE4":540,"NA":542},{"trials":523,"activeCount":12},[],{"trials":525,"activeCount":12},[],{"trials":527,"activeCount":12},[528],{"nctId":529,"briefTitle":530,"status":349,"phases":531,"primaryCompletion":532,"completion":533,"start":534,"enrollment":340,"conditions":535,"interventions":537},"NCT03254927","A Study of CDX-3379 and Cetuximab and in Patients With Advanced Head and Neck Squamous Cell Carcinoma",[66],"2020-09-16","2020-12-16","2018-03-27",[536],"Advanced Head and Neck Squamous Cell Carcinoma",[520],{"trials":539,"activeCount":12},[],{"trials":541,"activeCount":12},[],{"trials":543,"activeCount":12},[],{"intervention":545,"totalTrials":188,"cells":546},"Combination of varlilumab and nivolumab",{"EARLY_PHASE1":547,"PHASE1":549,"PHASE2":551,"PHASE3":567,"PHASE4":569,"NA":571},{"trials":548,"activeCount":12},[],{"trials":550,"activeCount":12},[],{"trials":552,"activeCount":12},[553],{"nctId":554,"briefTitle":555,"status":91,"phases":556,"primaryCompletion":557,"completion":557,"start":558,"enrollment":559,"conditions":560,"interventions":566},"NCT02335918","A Dose Escalation and Cohort Expansion Study of Anti-CD27 (Varlilumab) and Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors",[65,66],"2018-12-12","2015-01",175,[561,562,563,564,565],"Squamous Cell Carcinoma of the Head and Neck (SCCHN)","Ovarian Carcinoma-Enrollment Completed","Colorectal Cancer (CRC)-Enrollment Completed","Renal Cell Carcinoma (RCC) (Phase ll Only)","Glioblastoma (GBM) (Phase ll Only)-Enrollment Completed",[545],{"trials":568,"activeCount":12},[],{"trials":570,"activeCount":12},[],{"trials":572,"activeCount":12},[],{"intervention":217,"totalTrials":188,"cells":574},{"EARLY_PHASE1":575,"PHASE1":577,"PHASE2":579,"PHASE3":585,"PHASE4":587,"NA":589},{"trials":576,"activeCount":12},[],{"trials":578,"activeCount":12},[],{"trials":580,"activeCount":12},[581],{"nctId":207,"briefTitle":208,"status":91,"phases":582,"primaryCompletion":210,"completion":211,"start":212,"enrollment":213,"conditions":583,"interventions":584},[66],[215],[217,198],{"trials":586,"activeCount":12},[],{"trials":588,"activeCount":12},[],{"trials":590,"activeCount":12},[],{"intervention":260,"totalTrials":188,"cells":592},{"EARLY_PHASE1":593,"PHASE1":595,"PHASE2":597,"PHASE3":603,"PHASE4":605,"NA":607},{"trials":594,"activeCount":12},[],{"trials":596,"activeCount":12},[],{"trials":598,"activeCount":12},[599],{"nctId":249,"briefTitle":250,"status":91,"phases":600,"primaryCompletion":252,"completion":253,"start":254,"enrollment":255,"conditions":601,"interventions":602},[66],[228,229,230,231,232,257,258],[260,234,235],{"trials":604,"activeCount":12},[],{"trials":606,"activeCount":12},[],{"trials":608,"activeCount":12},[],{"intervention":421,"totalTrials":188,"cells":610},{"EARLY_PHASE1":611,"PHASE1":613,"PHASE2":615,"PHASE3":621,"PHASE4":623,"NA":625},{"trials":612,"activeCount":12},[],{"trials":614,"activeCount":12},[],{"trials":616,"activeCount":12},[617],{"nctId":411,"briefTitle":412,"status":91,"phases":618,"primaryCompletion":414,"completion":415,"start":416,"enrollment":417,"conditions":619,"interventions":620},[66],[419],[402,421],{"trials":622,"activeCount":12},[],{"trials":624,"activeCount":12},[],{"trials":626,"activeCount":12},[],{"intervention":628,"totalTrials":188,"cells":629},"CDX-1401 in combination with Resiquimod and\u002For Poly-ICLC",{"EARLY_PHASE1":630,"PHASE1":632,"PHASE2":634,"PHASE3":650,"PHASE4":652,"NA":654},{"trials":631,"activeCount":12},[],{"trials":633,"activeCount":12},[],{"trials":635,"activeCount":12},[636],{"nctId":637,"briefTitle":638,"status":91,"phases":639,"primaryCompletion":640,"completion":641,"start":642,"enrollment":643,"conditions":644,"interventions":646},"NCT00948961","A Study of CDX-1401 in Patients With Malignancies Known to Express NY-ESO-1",[65,66],"2012-06","2014-02","2009-09",70,[645],"Advanced Malignancies",[628,647,648,649],"CDX-1401","Resiquimod","poly-ICLC",{"trials":651,"activeCount":12},[],{"trials":653,"activeCount":12},[],{"trials":655,"activeCount":12},[],{"intervention":647,"totalTrials":188,"cells":657},{"EARLY_PHASE1":658,"PHASE1":660,"PHASE2":662,"PHASE3":668,"PHASE4":670,"NA":672},{"trials":659,"activeCount":12},[],{"trials":661,"activeCount":12},[],{"trials":663,"activeCount":12},[664],{"nctId":637,"briefTitle":638,"status":91,"phases":665,"primaryCompletion":640,"completion":641,"start":642,"enrollment":643,"conditions":666,"interventions":667},[65,66],[645],[628,647,648,649],{"trials":669,"activeCount":12},[],{"trials":671,"activeCount":12},[],{"trials":673,"activeCount":12},[],{"intervention":648,"totalTrials":188,"cells":675},{"EARLY_PHASE1":676,"PHASE1":678,"PHASE2":680,"PHASE3":686,"PHASE4":688,"NA":690},{"trials":677,"activeCount":12},[],{"trials":679,"activeCount":12},[],{"trials":681,"activeCount":12},[682],{"nctId":637,"briefTitle":638,"status":91,"phases":683,"primaryCompletion":640,"completion":641,"start":642,"enrollment":643,"conditions":684,"interventions":685},[65,66],[645],[628,647,648,649],{"trials":687,"activeCount":12},[],{"trials":689,"activeCount":12},[],{"trials":691,"activeCount":12},[],{"intervention":649,"totalTrials":188,"cells":693},{"EARLY_PHASE1":694,"PHASE1":696,"PHASE2":698,"PHASE3":704,"PHASE4":706,"NA":708},{"trials":695,"activeCount":12},[],{"trials":697,"activeCount":12},[],{"trials":699,"activeCount":12},[700],{"nctId":637,"briefTitle":638,"status":91,"phases":701,"primaryCompletion":640,"completion":641,"start":642,"enrollment":643,"conditions":702,"interventions":703},[65,66],[645],[628,647,648,649],{"trials":705,"activeCount":12},[],{"trials":707,"activeCount":12},[],{"trials":709,"activeCount":12},[],{"intervention":431,"totalTrials":188,"cells":711},{"EARLY_PHASE1":712,"PHASE1":714,"PHASE2":716,"PHASE3":722,"PHASE4":724,"NA":726},{"trials":713,"activeCount":12},[],{"trials":715,"activeCount":12},[],{"trials":717,"activeCount":12},[718],{"nctId":423,"briefTitle":424,"status":91,"phases":719,"primaryCompletion":426,"completion":337,"start":427,"enrollment":428,"conditions":720,"interventions":721},[66],[17],[402,431],{"trials":723,"activeCount":12},[],{"trials":725,"activeCount":12},[],{"trials":727,"activeCount":12},[],{"intervention":367,"totalTrials":188,"cells":729},{"EARLY_PHASE1":730,"PHASE1":732,"PHASE2":734,"PHASE3":740,"PHASE4":742,"NA":744},{"trials":731,"activeCount":12},[],{"trials":733,"activeCount":12},[],{"trials":735,"activeCount":12},[736],{"nctId":347,"briefTitle":348,"status":349,"phases":737,"primaryCompletion":351,"completion":352,"start":353,"enrollment":354,"conditions":738,"interventions":739},[66],[356,357,358,359,360,361,362,363,364,365],[294,367],{"trials":741,"activeCount":12},[],{"trials":743,"activeCount":12},[],{"trials":745,"activeCount":12},[],{"intervention":747,"totalTrials":188,"cells":748},"Combination of varlilumab and ipilimumab",{"EARLY_PHASE1":749,"PHASE1":751,"PHASE2":753,"PHASE3":765,"PHASE4":767,"NA":769},{"trials":750,"activeCount":12},[],{"trials":752,"activeCount":12},[],{"trials":754,"activeCount":12},[755],{"nctId":756,"briefTitle":757,"status":349,"phases":758,"primaryCompletion":759,"completion":760,"start":252,"enrollment":72,"conditions":761,"interventions":763},"NCT02413827","A Study of Varlilumab (Anti-CD27) and Ipilimumab and CDX-1401 in Patients With Unresectable Stage III or IV Melanoma",[65,66],"2016-11-02","2016-11-09",[762],"Unresectable Stage III or Stage IV Melanoma",[747,764],"Cohort A: varlilumab & ipilimumab; Cohort B: varlilumab, ipilimumab, CDX-1401 & poly-ICLC",{"trials":766,"activeCount":12},[],{"trials":768,"activeCount":12},[],{"trials":770,"activeCount":12},[],{"intervention":764,"totalTrials":188,"cells":772},{"EARLY_PHASE1":773,"PHASE1":775,"PHASE2":777,"PHASE3":783,"PHASE4":785,"NA":787},{"trials":774,"activeCount":12},[],{"trials":776,"activeCount":12},[],{"trials":778,"activeCount":12},[779],{"nctId":756,"briefTitle":757,"status":349,"phases":780,"primaryCompletion":759,"completion":760,"start":252,"enrollment":72,"conditions":781,"interventions":782},[65,66],[762],[747,764],{"trials":784,"activeCount":12},[],{"trials":786,"activeCount":12},[],{"trials":788,"activeCount":12},[],{"intervention":790,"totalTrials":9,"cells":791},"CDX-0159",{"EARLY_PHASE1":792,"PHASE1":794,"PHASE2":846,"PHASE3":848,"PHASE4":850,"NA":852},{"trials":793,"activeCount":12},[],{"trials":795,"activeCount":12},[796,804,815,828,837],{"nctId":797,"briefTitle":798,"status":91,"phases":799,"primaryCompletion":800,"completion":800,"start":801,"enrollment":6,"conditions":802,"interventions":803},"NCT04538794","A Study of CDX-0159 in Patients With Chronic Spontaneous Urticaria",[65],"2023-01-17","2020-09-24",[15],[790,187],{"nctId":805,"briefTitle":806,"status":91,"phases":807,"primaryCompletion":808,"completion":808,"start":809,"enrollment":810,"conditions":811,"interventions":813},"NCT05031624","A Phase 1 Study of Subcutaneous CDX-0159 in Healthy Subjects",[65],"2022-01-14","2021-08-30",32,[812],"Healthy Subjects",[790,814],"Normal saline",{"nctId":816,"briefTitle":817,"status":91,"phases":818,"primaryCompletion":819,"completion":820,"start":821,"enrollment":822,"conditions":823,"interventions":827},"NCT04548869","A Single Dose Study of the Safety, Pharmacokinetics and Pharmacodynamics of CDX-0159 in Patients With Cold Contact Urticaria, Symptomatic Dermographism, or Cholinergic Urticaria",[65],"2022-12-16","2023-05-12","2020-11-24",41,[151,824,153,825,826],"Cold Contact Urticaria","Symptomatic Dermatographism","Cholinergic Urticaria",[790],{"nctId":829,"briefTitle":830,"status":91,"phases":831,"primaryCompletion":832,"completion":832,"start":833,"enrollment":834,"conditions":835,"interventions":836},"NCT04944862","A Study of CDX-0159 in Patients With Prurigo Nodularis",[65],"2023-07-31","2021-11-08",24,[86],[790,814],{"nctId":838,"briefTitle":839,"status":91,"phases":840,"primaryCompletion":841,"completion":842,"start":843,"enrollment":810,"conditions":844,"interventions":845},"NCT04146129","A Phase 1 Study of CDX-0159",[65],"2020-04-06","2020-06-26","2019-10-29",[812],[790,814],{"trials":847,"activeCount":12},[],{"trials":849,"activeCount":12},[],{"trials":851,"activeCount":12},[],{"trials":853,"activeCount":12},[],{"intervention":814,"totalTrials":9,"cells":855},{"EARLY_PHASE1":856,"PHASE1":858,"PHASE2":880,"PHASE3":882,"PHASE4":884,"NA":886},{"trials":857,"activeCount":12},[],{"trials":859,"activeCount":12},[860,864,868,872,876],{"nctId":797,"briefTitle":798,"status":91,"phases":861,"primaryCompletion":800,"completion":800,"start":801,"enrollment":6,"conditions":862,"interventions":863},[65],[15],[790,187],{"nctId":805,"briefTitle":806,"status":91,"phases":865,"primaryCompletion":808,"completion":808,"start":809,"enrollment":810,"conditions":866,"interventions":867},[65],[812],[790,814],{"nctId":178,"briefTitle":179,"status":91,"phases":869,"primaryCompletion":181,"completion":181,"start":182,"enrollment":183,"conditions":870,"interventions":871},[65],[185],[54,187],{"nctId":829,"briefTitle":830,"status":91,"phases":873,"primaryCompletion":832,"completion":832,"start":833,"enrollment":834,"conditions":874,"interventions":875},[65],[86],[790,814],{"nctId":838,"briefTitle":839,"status":91,"phases":877,"primaryCompletion":841,"completion":842,"start":843,"enrollment":810,"conditions":878,"interventions":879},[65],[812],[790,814],{"trials":881,"activeCount":12},[],{"trials":883,"activeCount":12},[],{"trials":885,"activeCount":12},[],{"trials":887,"activeCount":12},[],{"intervention":889,"totalTrials":31,"cells":890},"KTN3379",{"EARLY_PHASE1":891,"PHASE1":893,"PHASE2":926,"PHASE3":928,"PHASE4":930,"NA":932},{"trials":892,"activeCount":12},[],{"trials":894,"activeCount":12},[895,905,915],{"nctId":896,"briefTitle":897,"status":91,"phases":898,"primaryCompletion":899,"completion":900,"start":901,"enrollment":173,"conditions":902,"interventions":904},"NCT02473731","A Window of Opportunity Study of KTN3379 in Surgically Resectable Head and Neck Cancer Patients",[65],"2016-09-22","2016-10-10","2015-10",[903],"Squamous Cell Carcinoma of the Head and Neck",[889],{"nctId":906,"briefTitle":907,"status":91,"phases":908,"primaryCompletion":909,"completion":909,"start":910,"enrollment":8,"conditions":911,"interventions":913},"NCT02456701","Enhancing Radioiodine Incorporation Into BRAF Mutant Thyroid Cancers With the Combination of Vemurafenib and KTN3379",[65],"2016-10-13","2015-06",[912],"Thyroid Cancer",[889,914],"vemurafenib",{"nctId":916,"briefTitle":917,"status":91,"phases":918,"primaryCompletion":919,"completion":920,"start":921,"enrollment":922,"conditions":923,"interventions":925},"NCT02014909","A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of KTN3379 in Adult Subjects With Advanced Tumors",[65],"2017-05-25","2017-06-05","2014-01",64,[924],"Advanced Cancer",[889],{"trials":927,"activeCount":12},[],{"trials":929,"activeCount":12},[],{"trials":931,"activeCount":12},[],{"trials":933,"activeCount":12},[],{"intervention":914,"totalTrials":188,"cells":935},{"EARLY_PHASE1":936,"PHASE1":938,"PHASE2":944,"PHASE3":946,"PHASE4":948,"NA":950},{"trials":937,"activeCount":12},[],{"trials":939,"activeCount":12},[940],{"nctId":906,"briefTitle":907,"status":91,"phases":941,"primaryCompletion":909,"completion":909,"start":910,"enrollment":8,"conditions":942,"interventions":943},[65],[912],[889,914],{"trials":945,"activeCount":12},[],{"trials":947,"activeCount":12},[],{"trials":949,"activeCount":12},[],{"trials":951,"activeCount":12},[],{"intervention":953,"totalTrials":188,"cells":954},"Combination of varlilumab and sunitinib",{"EARLY_PHASE1":955,"PHASE1":957,"PHASE2":977,"PHASE3":979,"PHASE4":981,"NA":983},{"trials":956,"activeCount":12},[],{"trials":958,"activeCount":12},[959],{"nctId":960,"briefTitle":961,"status":349,"phases":962,"primaryCompletion":963,"completion":964,"start":965,"enrollment":966,"conditions":967,"interventions":976},"NCT02386111","A Study of Varlilumab (Anti-CD27) and Sunitinib in Patients With Metastatic Clear Cell Renal Cell Carcinoma",[65],"2017-08","2017-11-03","2015-05",17,[968,969,30,970,971,972,973,974,975],"Carcinoma, Renal Cell","Kidney Diseases","Urogenital Neoplasms","Urologic Diseases","Urologic Neoplasms","Neoplasms","Neoplasms by Histologic Type","Clear-cell Metastatic Renal Cell Carcinoma",[953],{"trials":978,"activeCount":12},[],{"trials":980,"activeCount":12},[],{"trials":982,"activeCount":12},[],{"trials":984,"activeCount":12},[],{"intervention":986,"totalTrials":188,"cells":987},"Combination of Varlilumab and Atezolizumab",{"EARLY_PHASE1":988,"PHASE1":990,"PHASE2":1002,"PHASE3":1004,"PHASE4":1006,"NA":1008},{"trials":989,"activeCount":12},[],{"trials":991,"activeCount":12},[992],{"nctId":993,"briefTitle":994,"status":349,"phases":995,"primaryCompletion":996,"completion":997,"start":901,"enrollment":998,"conditions":999,"interventions":1001},"NCT02543645","A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer",[65],"2017-04","2017-05-22",18,[968,969,30,970,971,972,974,973,975,308,1000,21,24,26],"Triple Negative Breast Cancer",[986],{"trials":1003,"activeCount":12},[],{"trials":1005,"activeCount":12},[],{"trials":1007,"activeCount":12},[],{"trials":1009,"activeCount":12},[],{"intervention":330,"totalTrials":188,"cells":1011},{"EARLY_PHASE1":1012,"PHASE1":1014,"PHASE2":1020,"PHASE3":1022,"PHASE4":1024,"NA":1026},{"trials":1013,"activeCount":12},[],{"trials":1015,"activeCount":12},[1016],{"nctId":301,"briefTitle":302,"status":91,"phases":1017,"primaryCompletion":304,"completion":304,"start":305,"enrollment":306,"conditions":1018,"interventions":1019},[65],[308,26,17,309,310,19,311,312,313,28,314,315,24,316,317,318,319,320,321,322,323,324,325,326,327,328],[330,294,331,332],{"trials":1021,"activeCount":12},[],{"trials":1023,"activeCount":12},[],{"trials":1025,"activeCount":12},[],{"trials":1027,"activeCount":12},[],{"intervention":331,"totalTrials":188,"cells":1029},{"EARLY_PHASE1":1030,"PHASE1":1032,"PHASE2":1038,"PHASE3":1040,"PHASE4":1042,"NA":1044},{"trials":1031,"activeCount":12},[],{"trials":1033,"activeCount":12},[1034],{"nctId":301,"briefTitle":302,"status":91,"phases":1035,"primaryCompletion":304,"completion":304,"start":305,"enrollment":306,"conditions":1036,"interventions":1037},[65],[308,26,17,309,310,19,311,312,313,28,314,315,24,316,317,318,319,320,321,322,323,324,325,326,327,328],[330,294,331,332],{"trials":1039,"activeCount":12},[],{"trials":1041,"activeCount":12},[],{"trials":1043,"activeCount":12},[],{"trials":1045,"activeCount":12},[],{"intervention":1047,"totalTrials":188,"cells":1048},"CDX1307",{"EARLY_PHASE1":1049,"PHASE1":1051,"PHASE2":1064,"PHASE3":1066,"PHASE4":1068,"NA":1070},{"trials":1050,"activeCount":12},[],{"trials":1052,"activeCount":12},[1053],{"nctId":1054,"briefTitle":1055,"status":91,"phases":1056,"primaryCompletion":1057,"completion":1058,"start":1059,"enrollment":1060,"conditions":1061,"interventions":1063},"NCT00709462","A Study of CDX-1307, in Patients With Incurable Breast, Colorectal, Pancreatic, Ovarian or Bladder Cancer (CDX 1307-01)",[65],"2010-05","2010-06","2004-03",48,[17,28,1062,21,19],"Pancreatic Cancer",[1047],{"trials":1065,"activeCount":12},[],{"trials":1067,"activeCount":12},[],{"trials":1069,"activeCount":12},[],{"trials":1071,"activeCount":12},[],{"intervention":1073,"totalTrials":188,"cells":1074},"CDX-014",{"EARLY_PHASE1":1075,"PHASE1":1077,"PHASE2":1093,"PHASE3":1095,"PHASE4":1097,"NA":1099},{"trials":1076,"activeCount":12},[],{"trials":1078,"activeCount":12},[1079],{"nctId":1080,"briefTitle":1081,"status":349,"phases":1082,"primaryCompletion":1083,"completion":1083,"start":1084,"enrollment":1085,"conditions":1086,"interventions":1092},"NCT02837991","A Dose Escalation, Safety and Activity Study of CDX-014 in Patients With Renal Cell Carcinoma and Ovarian Clear Cell Carcinoma",[65],"2018-11-16","2016-06",16,[1087,1088,1089,30,1090,1091],"Renal Cell Carcinoma (RCC)","Clear-cell Renal Cell Carcinoma","Papillary Renal Cell Carcinoma","Metastatic Renal Cell Carcinoma","Ovarian Clear Cell Carcinoma",[1073],{"trials":1094,"activeCount":12},[],{"trials":1096,"activeCount":12},[],{"trials":1098,"activeCount":12},[],{"trials":1100,"activeCount":12},[],{"intervention":1102,"totalTrials":188,"cells":1103},"CDX-585",{"EARLY_PHASE1":1104,"PHASE1":1106,"PHASE2":1118,"PHASE3":1120,"PHASE4":1122,"NA":1124},{"trials":1105,"activeCount":12},[],{"trials":1107,"activeCount":12},[1108],{"nctId":1109,"briefTitle":1110,"status":91,"phases":1111,"primaryCompletion":1112,"completion":1112,"start":1113,"enrollment":1114,"conditions":1115,"interventions":1117},"NCT05788484","A Study of CDX-585 in Patients With Advanced Malignancies",[65],"2025-05-21","2023-05-11",20,[26,309,24,19,1116,317,312,28,314,315,310,311,1062,318],"Primary Peritoneal Carcinoma",[1102],{"trials":1119,"activeCount":12},[],{"trials":1121,"activeCount":12},[],{"trials":1123,"activeCount":12},[],{"trials":1125,"activeCount":12},[],{"intervention":1127,"totalTrials":188,"cells":1128},"CDX-0158",{"EARLY_PHASE1":1129,"PHASE1":1131,"PHASE2":1143,"PHASE3":1145,"PHASE4":1147,"NA":1149},{"trials":1130,"activeCount":12},[],{"trials":1132,"activeCount":12},[1133],{"nctId":1134,"briefTitle":1135,"status":91,"phases":1136,"primaryCompletion":1137,"completion":1138,"start":1139,"enrollment":1140,"conditions":1141,"interventions":1142},"NCT02642016","A Study to Evaluate the Safety and Pharmacokinetics of CDX-0158 in Adult Patients With Advanced Solid Tumors",[65],"2018-01-30","2019-06-04","2015-12",28,[924],[1127],{"trials":1144,"activeCount":12},[],{"trials":1146,"activeCount":12},[],{"trials":1148,"activeCount":12},[],{"trials":1150,"activeCount":12},[],{"intervention":1152,"totalTrials":188,"cells":1153},"CDX-1135",{"EARLY_PHASE1":1154,"PHASE1":1156,"PHASE2":1168,"PHASE3":1170,"PHASE4":1172,"NA":1174},{"trials":1155,"activeCount":12},[],{"trials":1157,"activeCount":12},[1158],{"nctId":1159,"briefTitle":1160,"status":349,"phases":1161,"primaryCompletion":1162,"completion":1162,"start":338,"enrollment":188,"conditions":1163,"interventions":1167},"NCT01791686","Clinical Trial of CDX-1135 in Pediatric and Adult Patients With Dense Deposit Disease",[65],"2014-03",[1164,1165,1166],"Dense Deposit Disease","Membranoproliferative Glomerulonephritis Type II","C3 Glomerulonephritis",[1152],{"trials":1169,"activeCount":12},[],{"trials":1171,"activeCount":12},[],{"trials":1173,"activeCount":12},[],{"trials":1175,"activeCount":12},[],{"intervention":1177,"totalTrials":188,"cells":1178},"CDX-1127",{"EARLY_PHASE1":1179,"PHASE1":1181,"PHASE2":1200,"PHASE3":1202,"PHASE4":1204,"NA":1206},{"trials":1180,"activeCount":12},[],{"trials":1182,"activeCount":12},[1183],{"nctId":1184,"briefTitle":1185,"status":91,"phases":1186,"primaryCompletion":1139,"completion":1187,"start":339,"enrollment":1188,"conditions":1189,"interventions":1199},"NCT01460134","A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers",[65],"2017-10-16",90,[1190,1191,320,1192,1193,1194,1195,1196,1197,1198],"CD27 Expressing B-cell Malignancies for Example Hodgkin's Lymphoma","Chronic Lymphocytic Leukemia","Marginal Zone B Cell Lymphoma)","Any T-cell Malignancy","Solid Tumors (Metastatic Melanoma, Renal (Clear) Cell Carcinoma","Hormone-refractory Prostate Adenocarcinoma, Ovarian Cancer","Colorectal Adenocarcinoma, Non-small Cell Lung Cancer)","Burkett's Lymphoma","Primary Lymphoma of the Central Nervous System",[1177,1177,1177],{"trials":1201,"activeCount":12},[],{"trials":1203,"activeCount":12},[],{"trials":1205,"activeCount":12},[],{"trials":1207,"activeCount":12},[],{"intervention":1209,"totalTrials":188,"cells":1210},"CDX-527",{"EARLY_PHASE1":1211,"PHASE1":1213,"PHASE2":1225,"PHASE3":1227,"PHASE4":1229,"NA":1231},{"trials":1212,"activeCount":12},[],{"trials":1214,"activeCount":12},[1215],{"nctId":1216,"briefTitle":1217,"status":91,"phases":1218,"primaryCompletion":1219,"completion":1219,"start":1220,"enrollment":1221,"conditions":1222,"interventions":1224},"NCT04440943","A Study of the PD-L1xCD27 Bispecific Antibody CDX-527 in Patients With Advanced Malignancies",[65],"2023-04-06","2020-08-04",27,[26,17,309,310,19,1116,317,311,312,1223,314,315,24,318],"MSI-H Colorectal Cancer",[1209],{"trials":1226,"activeCount":12},[],{"trials":1228,"activeCount":12},[],{"trials":1230,"activeCount":12},[],{"trials":1232,"activeCount":12},[],{"intervention":1234,"totalTrials":188,"cells":1235},"CDX-1307",{"EARLY_PHASE1":1236,"PHASE1":1238,"PHASE2":1249,"PHASE3":1251,"PHASE4":1253,"NA":1255},{"trials":1237,"activeCount":12},[],{"trials":1239,"activeCount":12},[1240],{"nctId":1241,"briefTitle":1242,"status":91,"phases":1243,"primaryCompletion":1244,"completion":1245,"start":1246,"enrollment":354,"conditions":1247,"interventions":1248},"NCT00648102","Phase I Study of CDX-1307, hCG-B Vaccine, for Patients With Incurable, Locally Advanced or Metastatic Breast, Colorectal, Pancreatic, Bladder or Ovarian Cancer",[65],"2009-05","2009-12","2006-01",[17,28,1062,21,19],[1234],{"trials":1250,"activeCount":12},[],{"trials":1252,"activeCount":12},[],{"trials":1254,"activeCount":12},[],{"trials":1256,"activeCount":12},[],{"intervention":474,"totalTrials":11,"cells":1258},{"EARLY_PHASE1":1259,"PHASE1":1261,"PHASE2":1263,"PHASE3":1269,"PHASE4":1271,"NA":1273},{"trials":1260,"activeCount":12},[],{"trials":1262,"activeCount":12},[],{"trials":1264,"activeCount":12},[1265],{"nctId":466,"briefTitle":467,"status":349,"phases":1266,"primaryCompletion":469,"completion":470,"start":471,"enrollment":306,"conditions":1267,"interventions":1268},[66],[308],[474,457,475,476],{"trials":1270,"activeCount":12},[],{"trials":1272,"activeCount":12},[],{"trials":1274,"activeCount":12},[1275],{"nctId":1276,"briefTitle":1277,"status":1278,"phases":1279,"conditions":1280,"interventions":1282},"NCT03067935","Individual Patient Expanded Access-Glembatumumab Vedotin","NO_LONGER_AVAILABLE",[],[1281],"Metastatic gpNMB Expressing Triple Negative Breast Cancer",[474],{"intervention":1284,"totalTrials":188,"cells":1285},"rindopepimut",{"EARLY_PHASE1":1286,"PHASE1":1288,"PHASE2":1290,"PHASE3":1292,"PHASE4":1294,"NA":1296},{"trials":1287,"activeCount":12},[],{"trials":1289,"activeCount":12},[],{"trials":1291,"activeCount":12},[],{"trials":1293,"activeCount":12},[],{"trials":1295,"activeCount":12},[],{"trials":1297,"activeCount":12},[1298],{"nctId":1299,"briefTitle":1300,"status":1278,"phases":1301,"conditions":1302,"interventions":1304},"NCT03068650","Expanded Access (Compassionate Use) Treatment Protocol Rindopepimut",[],[1303],"Recurrent GBM",[1284]]